PRILAGIN CREAM GIN 78G 2%+APPL

PRILAGIN

active ingredients

Vaginal solution 0.2%: 100 ml contain 0.2g of Miconazole. 400mg vaginal capsules: each capsule contains 400 mg of Miconazole nitrate. 1200mg vaginal capsules: each capsule contains 1200 mg of Miconazole nitrate. Gynecological cream 2%: 1 gram of gynecological cream contains 20 mg of nitrate Miconazole. Excipients with known effects: Prilagin 0.2% vaginal solution contains propylene glycol; Prilagin vaginal capsules contains etil p–hydroxybenzoate sodium and propil p–hydroxybenzoate sodium; Prilagin gynecological cream 2% contains benzoic acid and butilidroxyanionly. For the full list of excipients, see paragraph 6.1.

Excellent

Vaginal Solution: propylene glycol, lactic acid, phenossetol and undecilenoil (5) OE p–oxybenzoates, ricinoleilic alcohol (40) OE, purified water. 400 mg vaginal capsules: paraffin oil, white vaseline, gelatin, glycerin, titanium dioxide, etil p–hydroxybenzoate sodium, propil p–hydroxybenzoate sodium. 1200 mg vaginal capsules: paraffin oil, white vaseline, soy lethin, jelly, glycerin, titanium dioxide, etil p–hydroxybenzoate sodium, propil p–hydroxybenzoate sodium. Gynecological cream: palmitostearate of hetilenglycol and polyethyleneglycol, glycerides polyxyethylate glycolisates, liquid paraffin, butilidroxyanisol, benzoic acid, purified water.

Therapeutic indications

Vaginal solution Adjuvant in the therapy of vulvo–vaginal infections by Candida, although superinfected with Gram–positive germs; can also be used after other topical therapy or os, in order to reduce the risk of relapse. Vaginal capsules, gynecological cream Infections vulvo–vaginali from Candida. For its antibacterial action on Gram–positive bacteria, Prilagin can be used to treat mycosis with superinfections by such microorganisms. Prilagin generally exercises rapid action on itching that often accompanies infections caused by dermatophytes and Candida and this even before the appearance of curative action.

Contraindications

Hypersensitivity to the active ingredient, other derivatives of imidazole or any of the excipients listed in the paragraph 6.1.

Population

Vaginal solution: in the morning apply lavender in the vagina using the whole bottle: Daily applications can extend to doctor's judgment, over the normal 5–6 days of therapy. 400 mg vaginal capsules: for 3 days deeply introduce a capsule in the vagina in the evening before bedtime. 1200 mg vaginal capsules: deeply introduce a capsule into the vagina, the evening before bedtime. Treatment can be repeated in case of relapse. If symptomatology is particularly flourishing and pregnant patients, given the presence of the predisposing factor (graviance), it is advisable to prescribe from the beginning 2 days with 1200mg capsules. The complete treatment will also have to be performed during the very rapid disappearance of the symptoms of the disease and will also be continued during the menstrual period. Gynaecological cream: introduce once a day, deeply into the vagina, the evening before bedtime, the content of the applicator (5g cream). The treatment must be continued for at least 10 days, although itching and leucorrea have already disappeared. In case of failure, microbiological checks should be repeated to confirm the diagnosis.

Conservation

This medicine does not require any special condition of conservation.

Warnings

The use of latex condoms or diaphragms during treatment with anti-infective vaginal preparations may decrease the effectiveness of latex contraceptives. Therefore Prilagin should not be used at the same time as condoms or latex diaphragms.

Interactions

Interaction studies have not been carried out.

Effects

In the first weeks of miconazole therapy, disorders such as: burning and vaginal irritation, pelvic cramps, rarely skin rashes and headaches. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.aifa.gov.it/content/segnalazioni–reactions–adverse.

Overdosing

No overdose cases have been reported.

In case of pregnancy the product must be used only in case of actual need and under medical control.

Source: Farmadati